Neurobiological mechanisms of cannabinoid addiction

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2 SUPPL. 1, 2008, Pages

  Fattore, L ^a,b   Fadda, P ^b,c   Spano, M S ^b,c   Pistis, M ^b,c   Fratta, W ^a,b,c  

^a CNR   (Italy)

^b Center of Excellence Neurobiology of Dependence   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Abuse; CB1 receptor; Dependence; Endocannabinoid system; Relapse; Reward

Indexed keywords

CANNABINOID; CANNABIS; ENDOCANNABINOID;

AMYGDALOID NUCLEUS; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; DRUG ABUSE; DRUG DEPENDENCE; ELECTROPHYSIOLOGY; GLOBUS PALLIDUS; HIPPOCAMPUS; MICRODIALYSIS; NERVE ENDING; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

CANNABINOIDS; HUMANS; MARIJUANA ABUSE; NERVOUS SYSTEM;

EID: 42249091503     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.02.006     Document Type: Article

References (168)

1. Alici T., and Appel J.B. Increasing the selectivity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol: complete substitution with methanandamide. Pharmacol. Biochem. Behav. 79 (2004) 431-437
2. Anggadiredja K., Nakamichi M., Hiranita T., Tanaka H., Shoyama Y., Watanabe S., and Yamamoto T. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29 (2004) 1470-1478
3. Arnold J.C. The role of endocannabinoid transmission in cocaine addiction. Pharmacol. Biochem. Behav. 81 (2005) 396-406
4. Arnold J.C., Hunt G.E., and McGregor I.S. Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci. 70 (2001) 97-108
5. Arnone M., Maruani J., Chaperon F., Thiébot M.H., Poncelet M., Soubrié P., and Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132 (1997) 104-106
6. Balster R.L., and Prescott W.R. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Rev. 16 (1992) 55-62
7. Bisogno T., and Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol. Res. 56 (2007) 428-442
8. Bortolato M., Campolongo P., Manieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Calignano A., Gessa G.L., Cuomo V., and Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31 (2006) 2652-2659
9. Bozarth M.A., and Wise R.A. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224 (1984) 516-517
10. Braida D., Pozzi M., Parolaro D., and Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur. J. Pharmacol. 413 (2001) 227-234
11. Braida D., Limonta V., Pegorini S., Zani A., Guerini-Rocco C., Gori E., and Sala M. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology 190 (2007) 441-448
12. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., Mascia P., Zani A., Gori E., Fratta W., Parolaro D., and Sala M. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biol. Psychiatry 63 (2007) 286-292
13. Cahill, K., Ussher, M., 2007. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst. Rev. 17 CD005353.
14. Cappell H., Kuchar E., and Webster C.D. Some correlates of marihuana self-administration in man: a study of titration of intake as a function of drug potency. Psychopharmacologia 29 (1973) 177-184
15. Cardinal R.N., Parkinson J.A., Hall J., and Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 26 (2002) 321-352
16. Castañeda E., Moss D.E., Oddie S.D., and Whishaw I.Q. THC does not affect striatal dopamine release: microdialysis in freely moving rats. Pharmacol. Biochem. Behav. 40 (1991) 587-591
17. Chait L.D., and Zacny J.P. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology 107 (1992) 255-262
18. Cheer J.F., Wassum K.M., Heien M.L., Phillips P.E., and Wightman R.M. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J. Neurosci. 24 (2004) 4393-4400
19. Chen J., Paredes W., Lowinson J.H., and Gardner E.L. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur. J. Pharmacol. 190 (1990) 259-262
20. Chen J.P., Paredes W., Lowinson J.H., and Gardner E.L. Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci. Lett. 129 (1991) 136-180
21. Chen J., Marmur R., Pulles A., Paredes W., and Gardner E.L. Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient. Brain Res. 621 (1993) 65-70
22. Cippitelli A., Bilbao A., Hansson A.C., del Arco I., Sommer W., Heilig M., Massi M., Bermúdez-Silva F.J., Navarro M., Ciccocioppo R., and de Fonseca F.R. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur. J. Neurosci. 21 (2005) 2243-2251
23. Cohen C., Kodas E., and Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. 81 (2005) 387-395
24. Cossu G., Ledent C., Fattore L., Imperato A., Böhme G.A., Parmentier M., and Fratta W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res. 118 (2001) 61-65
25. De Vries T.J., and Schoffelmeer A.N. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci. 26 (2005) 420-426
26. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J., and Schoffelmeer A.N. A cannabinoid mechanism in relapse to cocaine seeking. Nat. Med. 7 (2001) 1151-1154
27. De Vries T.J., Homberg J.R., Binnekade R., Raasø H., and Schoffelmeer A.N. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168 (2003) 164-169
28. De Vries T.J., de Vries W., Janssen M.C., and Schoffelmeer A.N. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav. Brain Res. 161 (2005) 164-168
29. Degroot A., and Nomikos G.G. In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr. Opin. Pharmacol. 7 (2007) 62-68
30. Deiana S., Fattore L., Spano M.S., Cossu G., Porcu E., Fadda P., and Fratta W. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 52 (2007) 646-654
31. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5274-5278
32. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 585-589
33. Di Marzo V., Goparaju S.K., Wang L., Liu J., Bátkai S., Járai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
34. Diana M., Pistis M., Carboni S., Gessa G.L., and Rossetti Z.L. Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 7966-7969
35. Diana M., Pistis M., Muntoni A., and Gessa G. Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats. J. Pharmacol. Exp. Ther. 272 (1995) 781-785
36. Diana M., Melis M., Muntoni A.L., and Gessa G.L. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 10269-10273
37. Doty P., Dykstra L.A., and Picker M.J. Discriminative stimulus effects of phencyclidine: pharmacologically specific interactions with delta9- and delta8-tetrahydrocannabinol. Drug Alcohol Depend. 35 (1994) 151-158
38. Economidou D., Mattioli L., Cifani C., Perfumi M., Massi M., Cuomo V., Trabace L., and Ciccocioppo R. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 183 (2006) 394-403
39. Economidou D., Mattioli L., Ubaldi M., Lourdusamy A., Soverchia L., Hardiman G., Campolongo P., Cuomo V., and Ciccocioppo R. Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol. Toxicol. Appl. Pharmacol. 223 (2007) 73-85
40. Einhorn L.C., Johansen P.A., and White F.J. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J. Neurosci. 8 (1988) 100-112
41. Everitt B.J., and Wolf M.E. Psychomotor stimulant addiction: a neural systems perspective. J. Neurosci. 22 (2002) 3312-3320
42. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., and Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N. Y. Acad. Sci. 877 (1999) 412-438
43. Fadda P., Scherma M., Fresu A., Collu M., and Fratta W. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 50 (2003) 1-6
44. Fadda P., Scherma M., Spano M.S., Salis P., Melis V., Fattore L., and Fratta W. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 17 (2006) 1629-1632
45. Fattore L., Cossu G., Martellotta C.M., and Fratta W. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 156 (2001) 410-416
46. Fattore L., Cossu G., and Fratta W. Functional interaction between cannabinoids and opioids in animal models of drug addiction. Proceedings of the "Frontiers in Addiction Research" NIDA Symposium Satellite at the SfN Meeting. Orlando (USA), November 1-2 (2002)
47. Fattore L., Spano M.S., Cossu G., Deiana S., and Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur. J. Neurosci. 17 (2003) 1723-1726
48. Fattore L., Cossu G., Spano M.S., Deiana S., Fadda P., Scherma M., and Fratta W. Cannabinoids and reward: interactions with the opioid system. Crit. Rev. Neurobiol. 16 (2004) 147-158
49. Fattore L., Deiana S., Spano M.S., Cossu G., Fadda P., Scherma M., and Fratta W. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol. Biochem. Behav. 81 (2005) 343-359
50. Fattore L., Spano M.S., Cossu G., Deiana S., Fadda P., and Fratta W. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 8 (2005) 1097-1104
51. Fattore L., Fadda P., and Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol. Res. 56 (2007) 418-427
52. Fattore L., Spano M.S., Altea S., Angius F., Fadda P., and Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br. J. Pharmacol. 152 (2007) 795-804
53. Fattore L., Spano M.S., Deiana S., Melis V., Cossu G., Fadda P., and Fratta W. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res. Rev. 53 (2007) 1-16
54. Fattore L., Viganò D., Fadda P., Rubino T., Fratta W., and Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur. J. Neurosci. 25 (2007) 2191-2200
55. Fattore L., Altea S., and Fratta W. Sex differences in drug addiction: a review of animal and human studies. Women's Health 4 (2008) 51-65
56. Filip M., Gołda A., Zaniewska M., McCreary A.C., Nowak E., Kolasiewicz W., and Przegaliński E. Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine. Pharmacol. Rep. 58 (2006) 806-819
57. Foltin R.W., Fischman M.W., Brady J.V., Capriotti R.M., and Emurian C.S. The regularity of smoked marijuana self-administration. Pharmacol. Biochem. Behav. 32 (1989) 483-486
58. Forget B., Barthélémy S., Saurini F., Hamon M., and Thiébot M.H. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology 189 (2006) 59-69
59. Fratta W., Cossu G., Martellotta M.C., and Fattore L. A common neurobiological mechanism regulates cannabinoid and opioid rewarding effects in mice. Neurosci. Lett. 52 (1999) S10-S11
60. French E.D., Dillon K., and Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8 (1997) 649-652
61. Gardner E.L. Brain reward mechanisms. In: Lowinson J.H., Ruiz P., Millman R.B., and Langrod J.G. (Eds). Substance Abuse: A Comprehensive Textbook (1997), Williams & Wilkins, Baltimore 51-85
62. Gardner E.L. What we have learned about addiction from animal models of drug self-administration. Am. J. Addict. 9 (2000) 285-313
63. Gardner E.L. Addictive potential of cannabinoids: the underlying neurobiology. Chem. Phys. Lipids 121 (2002) 267-290
64. Gardner E.L., and Lowinson J.H. Marijuana's interaction with brain reward systems: update 1991. Pharmacol. Biochem. Behav. 40 (1991) 571-580
65. Gardner E.L., and Vorel S.R. Cannabinoid transmission and reward-related events. Neurobiol. Dis. 5 (1998) 502-533
66. Gardner E.L., Paredes W., Smith D., Donner A., Milling C., Cohen D., and Morrison D. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol. Psychopharmacology 96 (1988) 142-144
67. Gessa G.L., Muntoni F., Collu M., Vargiu L., and Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 348 (1985) 201-203
68. Gessa G.L., Melis M., Muntoni A.L., and Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 341 (1998) 39-44
69. Gómez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., Nava F., Piomelli D., and Rodríguez de Fonseca F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 22 (2002) 9612-9617
70. Gonon F.G. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24 (1988) 19-28
71. Grace A.A., and Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons. 1. Identification and characterization. Neuroscience 10 (1983) 301-315
72. Groenewegen H.J., and Russchen F.T. Organization of the efferent projections of the nucleus accumbens to pallidal, hypothalamic, and mesencephalic structures: a tracing and immunohistochemical study in the cat. J. Comp. Neurol. 223 (1984) 347-367
73. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32 (2007) 1391-1403
74. Haney M., Comer S.D., Ward A.S., Foltin R.W., and Fischman M.W. Factors influencing marijuana self-administration by humans. Behav. Pharmacol. 8 (1997) 101-112
75. Haney M., Ward A.S., Comer S.D., Foltin R.W., and Fischman M.W. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141 (1999) 385-394
76. Henriksson B.G., Johansson J.O., and Järbe T.U. Delta 9-tetrahydrocannabinol produced discrimination in pigeons. Pharmacol. Biochem. Behav. 3 (1975) 771-774
77. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11 (1991) 563-583
78. Hochman J.S., and Brill N.Q. Marijuana intoxication: pharmacological and psychological factors. Dis. Nerv. Syst. 32 (1971) 676-679
79. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 38 (1986) 1-20
80. Ikemoto S., and Wise R.A. Mapping of chemical trigger zones for reward. Neuropharmacology 47 (2004) 190-201
81. Ito R., Robbins T.W., and Everitt B.J. Differential control over cocaine-seeking behavior by nucleus accumbens core and shell. Nat. Neurosci. 7 (2004) 389-397
82. Järbe T.U., Johansson J.O., and Henriksson B.G. Delta9-tetrahydrocannabinol and pentobarbital as discriminative cues in the Mongolian Gerbil (Meriones unguiculatus). Pharmacol. Biochem. Behav. 3 (1975) 403-410
83. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12 (1992) 483-488
84. Jones R.T. Marihuana-induced "high": influence of expectation, setting and previous drug experience. Pharmacol. Rev. 23 (1971) 359-369
85. Julian M.D., Martin A.B., Cuellar B., Rodriguez De Fonseca F., Navarro M., Moratalla R., and Garcia-Segura L.M. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119 (2003) 309-318
86. Justinova Z., Tanda G., Redhi G.H., and Goldberg S.R. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 169 (2003) 135-140
87. Justinova Z., Solinas M., Tanda G., Redhi G.H., and Goldberg S.R. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J. Neurosci. 25 (2005) 5645-5650
88. Kelley A.E. Ventral striatal control of appetitive motivation: role in ingestive behavior and reward-related learning. Neurosci. Biobehav. Rev. 27 (2004) 765-776
89. Kelly T.H., Foltin R.W., Emurian C.S., and Fischman M.W. Effects of delta 9-THC on marijuana smoking, dose choice, and verbal report of drug liking. J. Exp. Anal. Behav. 61 (1994) 203-211
90. Kelly T.H., Foltin R.W., Mayr M.T., and Fischman M.W. Effects of delta 9-tetrahydrocannabinol and social context on marijuana self-administration by humans. Pharmacol. Biochem. Behav. 49 (1994) 763-768
91. Kelly T.H., Foltin R.W., Emurian C.S., and Fischman M.W. Are choice and self-administration of marijuana related to delta 9-THC content?. Exp. Clin. Psychopharmacol. 5 (1997) 74-82
92. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N. Y. Acad. Sci. 654 (1992) 171-191
93. Laszlo J., Lucas Jr. V.S., Hanson D.C., Cronin C.M., and Sallan S.E. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J. Clin. Pharmacol. 21 (1981) 51S-56S
94. Laviolette S.R., and Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell. Mol. Life Sci. 63 (2006) 1597-1613
95. Le Foll B., and Goldberg S.R. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. 312 (2005) 875-883
96. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
97. Lepore M., Liu X., Savage V., Matalon D., and Gardner E.L. Genetic differences in delta9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sci. 58 (1996) PL365-PL372
98. Lindgren J.E., Ohlsson A., Agurell S., Hollister L., and Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74 (1981) 208-212
99. Lupica C.R., and Riegel A.C. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48 (2005) 1105-1116
100. Mangieri R.A., and Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol. Res. 56 (2007) 360-366
101. Marinelli M., Rudick C.N., Hu X.T., and White F.J. Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol. Disord. Drug Targets 5 (2006) 79-97
102. Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M.T., van der Stelt M., Bernardi G., Molinari M., Maccarrone M., and Mercuri N.B. N-Arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 (2007) 298-308
103. Marsicano G., and Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 11 (1999) 4213-4225
104. Martellotta M.C., Cossu G., Fattore L., Gessa G.L., and Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85 (1998) 327-330
105. Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Böhme G.A., Imperato A., and Fratta W. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur. J. Pharmacol. 383 (1999) R1-R2
106. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327 (1993) 535-550
107. Matthews R.T., and German D.C. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience 11 (1984) 617-625
108. McGregor I.S., Dam K.D., Mallet P.E., and Gallate J.E. Delta9-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: comparison with midazolam, food deprivation and predator odour. Alcohol Alcohol. 40 (2005) 35-45
109. McRae A.L., Budney A.J., and Brady K.T. Treatment of marijuana dependence: a review of the literature. J. Subst. Abuse Treat. 24 (2003) 369-376
110. Mechoulam R., and Parker L. Cannabis and alcohol-a close friendship. Trends Pharmacol. Sci. 24 (2003) 266-268
111. Melis M., and Pistis M. Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?. Curr. Neuropharmacol. 5 (2007) 268-277
112. Melis M., Perra S., Muntoni A.L., Pillola G., Lutz B., and Marsicano G. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J. Neurosci. 24 (2004) 10707-10715
113. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., and Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 24 (2004) 53-62
114. Melis M., Pillolla G., Bisogno T., Minassi A., Petrosino S., Perra S., Muntoni A.L., Lutz B., Gessa G.L., Marsicano G., Di Marzo V., and Pistis M. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiol. Dis. 24 (2006) 15-27
115. Mendelson J.H., and Mello N.K. Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83 (1984) 351-356
116. Mendelson J.H., Mello N.K., Lex B.W., and Bavli S. Marijuana withdrawal syndrome in a woman. Am. J. Psychiatry 141 (1984) 1289-1290
117. Mereu G., Yoon K.W., Boi V., Gessa G.L., Naes L., and Westfall T.C. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur. J. Pharmacol. 141 (1987) 395-399
118. Micale V., Mazzola C., and Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol. Res. 56 (2007) 382-392
119. Mokler D.J., Nelson B.D., Harris L.S., and Rosecrans J.A. The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol. Life Sci. 38 (1986) 1581-1589
120. Moore B.A., and Budney A.J. Relapse in outpatient treatment for marijuana dependence. J. Subst. Abuse Treat. 25 (2003) 85-89
121. Murray R.M., Morrison P.D., Henquet C., and Di Forti M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 8 (2007) 885-895
122. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., Chowen J.A., Gomez R., del Arco I., Villanua M.A., Maldonado R., Koob G.F., and Rodriguez de Fonseca F. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J. Neurosci. 21 (2001) 5344-5350
123. Ng Cheong Ton J.M., Gerhardt G.A., Friedemann M., Etgen A.M., Rose G.M., Sharpless N.S., and Gardner E.L. The effects of delta9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res. 451 (1988) 59-68
124. Noyes Jr. R., Brunk S.F., Baram D.A., and Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. 15 (1975) 139-143
125. Ohlsson A., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., and Gillespie H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28 (1980) 409-416
126. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J. Psychopharmacol. 20 (2006) 147-163
127. Pettit H.O., and Justice Jr. J.B. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol. Biochem. Behav. 34 (1989) 899-904
128. Pistis M., Ferraro L., Pira L., Flore G., Tanganelli S., Gessa G.L., and Devoto P. Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 948 (2002) 155-158
129. Pistis M., Muntoni A.L., Pillolla G., and Gessa G.L. Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur. J. Neurosci. 15 (2002) 1795-1802
130. Pistis M., Muntoni A.L., Pillolla G., Perra S., Cignarella G., Melis M., and Gessa G.L. Gamma-hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABA(B) receptor-mediated effects. Neuroscience 131 (2005) 465-474
131. Pontieri F.E., Tanda G., and Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 12304-12308
132. Racz I., Bilkei-Gorzo A., Toth Z.E., Michel K., Palkovits M., and Zimmer A. A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. J. Neurosci. 23 (2003) 2453-2458
133. Raft D., Gregg J., Ghia J., and Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21 (1977) 26-33
134. Riegel A.C., and Lupica C.R. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J. Neurosci. 24 (2004) 11070-11078
135. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 80 (1998) 1-27
136. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
137. Schultz W. Behavioral theories and the neurophysiology of reward. Annu. Rev. Psychol. 57 (2006) 87-115
138. Schultz W., and Dickinson A. Neuronal coding of prediction errors. Annu. Rev. Neurosci. 23 (2000) 473-500
139. Serra G., and Fratta W. A possible role for the endocannabinoid system in the neurobiology of depression. Clin. Pract. Epidemol. Ment. Health 19 3 (2007) 25
140. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 54 (2007) 438-444
141. Solinas M., Panlilio L.V., Justinova Z., Yasar S., and Goldberg S.R. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat. Protoc. 1 (2006) 1194-1206
142. Solinas M., Scherma M., Fattore L., Stroik J., Wertheim C., Tanda G., Fratta W., and Goldberg S.R. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J. Neurosci. 27 (2007) 5615-5620
143. Solinas M., Yasar S., and Goldberg S.R. Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol. Res. 56 (2007) 393-405
144. Spano M.S., Fattore L., Cossu G., Deiana S., Fadda P., and Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br. J. Pharmacol. 143 (2004) 343-350
145. Spano M.S., Ellgren M., Wang X., and Hurd Y.L. Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol. Psychiatry 61 (2007) 554-563
146. Spear S.F., Ciesla J.R., and Skala S.Y. Relapse patterns among adolescents treated for chemical dependency. Subst. Use Misuse 34 (1999) 1795-1815
147. Stephens R.S., Roffman R.A., and Simpson E.E. Treating adult marijuana dependence: a test of the relapse prevention model. J. Consult. Clin. Psychol. 62 (1994) 92-99
148. Szabo B., Siemes S., and Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci. 15 (2002) 2057-2061
149. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276 (1997) 2048-2050
150. Thanos P.K., Dimitrakakis E.S., Rice O., Gifford A., and Volkow N.D. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav. Brain Res. 164 (2005) 206-213
151. Trojniar W., and Wise R.A. Facilitory effect of delta 9-tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology 103 (1991) 172-176
152. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56 (1998) 613-672
153. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12 (2007) 227-462
154. United Nations Office on Drugs and Crime (UNODC), 2006. UNODC World Drug Report. http://www.unodc.org/unodc/en/world_drug_report2006.html.
155. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
156. Viveros M.P., Marco E.M., and File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 81 (2005) 331-342
157. Viveros M.P., Marco E.M., and File S.E. Nicotine and cannabinoids: parallels, contrasts and interactions. Neurosci. Biobehav. Rev. 30 (2006) 1161-1181
158. Vlachou S., Nomikos G.G., and Panagis G. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology 179 (2005) 498-508
159. Voorn P., Gerfen C.R., and Groenewegen H.J. Compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine, and calcium-binding protein. J. Comp. Neurol. 289 (1989) 189-201
160. Wang G.J., Volkow N.D., Fowler J.S., Cervany P., Hitzemann R.J., Pappas N.R., Wong C.T., and Felder C. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci. 64 (1999) 775-784
161. Ward A.S., Comer S.D., Haney M., Foltin R.W., and Fischman M.W. The effects of a monetary alternative on marijuana self-administration. Behav. Pharmacol. 8 (1997) 275-286
162. Wenger T., Moldrich G., and Furst S. Neuromorphological background of cannabis addiction. Brain Res. Bull. 61 (2003) 125-128
163. Wiley J.L., and Martin B.R. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination. Pharmacol. Biochem. Behav. 64 (1999) 519-522
164. Wiley J.L., Huffman J.W., Balster R.L., and Martin B.R. Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend. 40 (1995) 81-86
165. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 5 (2004) 483-494
166. Xi Z.X., Gilbert J.G., Peng X.Q., Pak A.C., Li X., and Gardner E.L. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J. Neurosci. 26 (2006) 8531-8536
167. Yanovsky Y., Mades S., and Misgeld U. Retrograde signaling changes the venue of postsynaptic inhibition in rat substantia nigra. Neuroscience 122 (2003) 317-328
168. Zahm D.S., and Brog J.S. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience 50 (1992) 751-767